Pharma & COVID-19: Winners, losers, prospects
19 November 2020
Our third dialogue in a series of online discussions on key access to medicines (A2M) priorities bringing together thought leaders and policy-makers, academics, industry representatives and NGOs, for a frank discussion of European pharmaceutical policies.
Take part in our #A2MDialogues to share your questions and ideas and help us develop actionable #A2Msolutions for decision-makers in Europe.
Is the affordability debate in Europe changing in the light of COVID-19?
Who are the big winners and losers?
From the onset of the COVID-19 pandemic, governments turned to the pharmaceutical sector for answers and solutions. Almost a year later, we look at how the present pandemic has reshaped the dynamics within the sector, as well as the power balance between this diverse business sector and European governments. What are the trends for the near future?
We will hear from a venture capitalist investing in pharma, a leading access to medicines advocate, an expert in the science and economics of drug R&D, and the advocacy director of an alternative drug development model.
Deputy Managing Partner, Albion VC
Dr Els Torreele
Visiting Policy Fellow, Institute for Innovation and Public Purpose
Innogen Associate & Honorary Fellow, School of Social and Political Science, University of Edinburgh
Director of Policy Advocacy, DNDi
EPHA’s series of online discussions on key access to medicines (A2M) priorities brings together thought leaders and policy-makers, academics, industry representatives and NGOs, for a frank discussion of European pharmaceutical policies.